Method for using water with active oxygen forms (oxygen water) for skin care

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to cosmetology and can be used for skin care. For this purpose, artesian water synthetically enriched with active oxygen forms is used. It is applied on face or body skin by means of a guided pulveriser-sprayer.

EFFECT: method provides minimum duration of application of irrigation procedure, enables the permanent intended use regardless of time and a place.

 

The invention relates to the field of "beauty industry", such as: skin care face and body, cosmetology, makeup, and based on the method of application of artesian water with active forms of oxygen (oxygen water) on the face or the body by means of a device for directional spray (spray) fluid.

The effect of water with active forms of oxygen (oxygen water on the skin is characterized as hydration and oxygenation - the higher oxygen content in the tissues of the skin, improves the rheological properties and activates blood microcirculation, increases the supply of oxygen to tissues.

Among the most known methods of oxygen therapy: hyperbaric oxygen therapy and oxygen therapy using drugs. Hyperbaric oxygen therapy is forced oxygenation supplied to the chamber under high pressure. This procedure requires a visit to the cosmetic clinic, as a consequence pre-approval procedures, the loss of time for the procedure itself and on the way there/back.

Among drugs, engaged in oxygenation, you can select products company Faberlic that contains the formula of oxygen "Novaftem-O", which is included in creams, masks and balms. Thus, there is a method of skin care based on the use of water from the active formanilide, consisting in the simultaneous hydration and its saturation with oxygen (patent RF №2211024 from 27.08.2003, class A61K 7/48). The use of this drug is closest to the proposed method, because the skin at the same time moistened and saturated with oxygen.

The disadvantage is the inability to use, at any time, for example, deposited on the face of decorative cosmetics, transport, office, etc.

Technical challenges are addressed by the invention are the minimum application procedure irrigation, the possibility of permanent use as needed regardless of time and place.

The technical problem solved by the fact that in skin care, based on the method of use of water with active forms of oxygen, consisting in the simultaneous hydration of the skin and saturate it with oxygen, artesian water, artificially enriched with active forms of oxygen, which is applied to the skin of the face or body by means of a device for directional spray - atomization of the liquid.

Irrigation efficiency oxygen water greatly depends on the fineness and quality of spraying, under which understand the degree of dispersion of the torch drops. Thus, to achieve the desired result it is necessary to use the tank, to the second oxygen water is pushed or placed in the vessel with an inert gas propylene, either by building the capacity of excess pressure pump and then through a spray head fine dispersion. A necessary condition for the preservation of active forms of oxygen in the oxygen water when using aerosol packaging is their high initial content of not less than 15 mg/L.

In addition, when spraying is provided such droplet sizes, which form water and oxygen cloud. The minimum droplet size (less than 30 microns) facilitate instant skin absorption of oxygen water, which in turn leads to increased circulation of blood enriched with oxygen, and, last but not least, do not damage the makeup.

As the original product artesian water with active forms of oxygen or any other with the oxygen content of not less than 15 mg/L.

Aerosol packaging.

For aerosol packaging uses compressed nitrogen according to GOST 9293-74, acts as a displacer of the product. Tanks-tanks aluminum monoblock (GOST 26220). Test pressure of 1.2 MPa should not cause residual strain. Internal coating of varnish/enamel mandatory. The valve of the aerosol (for compressed gas) - aluminum, coating with lacquer or enamel double-sided.

Spray head providing a thin dispersion at a level of not more than 30 μm.

Decorative protective cap serves to protect the spray head from involuntary pressing and from the ingress of dust, dirt, etc.

The aerosol valves, spray heads, decorative caps must comply with the requirements of GOST 26891.

Spray packaging.

A distinctive feature of the spray-packaging of aerosol is the lack of a propellant. Accordingly, there is no need in aerosol valve. This significantly reduces the cost of the final product, however, the use of spray-packing is not as comfortable as aerosol, and most importantly, it is almost impossible to achieve fine dispersion during sputtering, which is a significant factor in favor of the aerosol package.

Tank - the tank of any material that is capable of long term contain no loss of quality water with active forms of oxygen (oxygen water), such as glass, PET, aluminium, etc.

Push button spray (spray) is a spray head combined in the same housing with the pump. Push-button dispensers come in a screw under execution and sealing.

Decorative protective cap serves to protect the spray head from involuntary pressing and from the ingress of dust, dirt, etc.

As an example, consider the aerosol container with a capacity of 75 ml (product who) drinking water with active forms of oxygen with an oxygen content of 25 mg/L.

Original aluminum canister with the following characteristics: the width of the throat is 24.5 mm, height 125 mm, diameter 35 mm) through the metering device bottling line is filled with drinking water with active forms of oxygen in a volume of 75 ml

Then the machine inserts into the neck of the container valve and flare skirt valve that rigidly secures the valve on the cylinder.

Next, the balloon is served in a special chamber, where it is established through the valve in a compressed nitrogen until a tank pressure of 0.7 MPa.

After that, the container passes through the measuring apparatus, which controls the weight of the product/container no leaks propylene and in case of deviations from the parameters rejects the cylinders.

The last step - putting a decorative cap (diameter 35 mm, height 40 mm) and packing in a cardboard box (228×152×161 mm) of 24 pieces with the separation of the cardboard strips.

Spraying water (irrigation) on the skin perform from a distance of 20-30 cm, and the container should be held upright, the spray head up.

Spraying formed water-oxygen cloud, which is when the skin absorbs instantly without the formation of droplets, drip.

Because when using the aerosol bottle of water with active forms of oxygen pursued voina goal hydration and increasing the level of oxygen in the tissues, the main difference of this method is the universality of its application. The insignificant size of the balloon to keep it to yourself, and fine dispersion is to use anytime and anywhere as needed. It should be noted that tissue oxygenation at the specified manner similar to preparative oxygenation is quite superficial and hold it a couple of times a day, but does not require the application of creams and masks - the whole procedure takes a few seconds.

The method of skin care based on the use of water with active forms of oxygen, consisting in the simultaneous hydration of the skin and saturate it with oxygen, characterized in that the artesian water, artificially enriched with active forms of oxygen, which is applied to the skin of the face or body by means of a device for directional spray-atomization of the liquid.



 

Same patents:

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary. The preparation contains the following drugs: L-arginine monohydrochloride in amount 48-72 mg/l, L-lysine monohydrochloride in amount 48-72 mg/l, L-histidine monohydrochloride in amount 13.8-20.8 mg/l, L-isoleucine in amount 13.8-20.8 mg/l, L-leucine in amount 41.6-62.4 mg/l, L-methionine in amount 10.4-15.6 mg/l, L-phenylalanine in amount 17.2-25.8 mg/l, L-threonine in amount 20.8-31.2 mg/l, L-tryptophan in amount 7.9-10.3 mg/l, L-glutamine in amount 68.8-103.2 mg/l, L-valine in amount 17.2-25.8 mg/l, L-tyrosine in amount 27.7-41.5 mg/l, L-cystine monochloride in amount 17.9-26.9 mg/l, L-serine in amount 17.2-25.8 mg/l, glycine in amount 34.4-54.6 mg/l, L-alpha-alanine in amount 17.2-25.8 mg/l, L-proline in amount 25.6-38.4 mg/l, L-aspartic acid in amount 18.0-30.0 mg/l, L-oxyproline in amount 7.9-10.3 mg/l, L-glutamic acid in amount 48-72 mg/l, L-cysteine monohydrochloride in amount 0.12-0.70 mg/l, choline chloride in amount 0.4-3.0 mg/l, folic acid in amount 0.01-0.09 mg/l, calcium pantothenate in amount 0.01-0.09 mg/l, thiamine hydrochloride in amount 0.01-0.09 mg/l, nicotinic acid in amount 0.03-0.22 mg/l, pyridoxal monohydrochloride in amount 0.03-0.22 mg/l, riboflavin in amount 0.012-0.09 mg/l, nicotinamide in amount 0.03-0.22 mg/l, D-biotin in amount 0.01-0.09 mg/l, myoinositol in amount 0.06-0.45 mg/l, pyridoxine hydrochloride in amount 0.03-0.22 mg/l, calciferol in amount 0.01-0.09 mg/l, ascorbic acid in amount 0.06-0.45 mg/l, p-amino-benzoic acid in amount 0.06-0.45 mg/l, glucose in amount 800-1200 mg/l, and the following inorganic salts: sodium chloride in amount 7.2-8.8 g/l, potassium chloride in amount 360-440 mg/l, one-substituted potassium phosphate in amount 54-66 mg/l, two-substituted 12-aqueous sodium phosphate in amount 13.5-16.5 mg/l, 6-aqueous calcium chloride in amount 24.8-30.4 mg/l, 6-aqueous magnesium chloride in amount 9.9-11.6 mg/l, 7-aqueous magnesium sulphate in amount 9.0-11.0 mg/l, 9-aqueous ferrous nitrate in amount 0.65-0.79 mg/l, 3-aqueous sodium acetate in amount 7.1-8.7 mg/l. The method for prevention and correction of diseased conditions in animals consists in the injection introduction in an animal of said preparation in the form of an aqueous solution for prevention 2 times a week for a month in dosage 1.5-2.0 ml per 10 kg of body weight, for therapy in dosage 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, at synthetic and/or food poisoning intoxications - in a tenfold therapeutic dose. And, if a dose of the preparation exceeds 20 ml, it is injected in more points.

EFFECT: invention provides higher therapeutic and preventive effectiveness.

6 cl, 8 tbl

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention relates to immunology and biotechnology. The invention discloses versions of a cytotoxically active CD3-specific binding structure. The structure comprises a first domain specifically binding to human CD3 and an Ig-derived second binding domain which is specific to molecules on the cell surface. The invention describes a coding nucleic acid, a vector for expressing the structure and an eukaryotic cell transformed by the vector. The invention discloses versions of compositions based on the structure for treating, preventing or alleviating various diseases and corresponding methods of treating the diseases. A method of obtaining the structure is disclosed.

EFFECT: use of the invention provides a structure with low immunological potency, which has cytotoxicity comparable to the initial structure, which may find further use in medicine.

60 cl, 18 dwg, 15 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of purifying plant extracts which mainly consist of noroxymorphone compounds and contain α,β-unsaturated noroxymorphone compounds as impurities, through (a) conversion of a plant extract or product of the next step in synthesis of the selected noroxymorphone compound as a result of conversion of hydroxyl groups present in the mixture to groups of formula -OR2 which can be split, in which R2 is an introduced radical of the said group which can be split, (b) said groups, if necessary, can be removed once more, after which (c) the obtained mixture is subjected to selective hydrogenation so that a saturated bond forms in the α,β-position of unsaturated noroxymorphone compounds and all the remaining groups which can be split are converted to a hydroxyl group, after which (d) a pure noroxymorphone compound is extracted; processing the purified noroxymorphone to naltrexone or naloxone or a salt of these compounds or a quaternary derivative of these compounds, which are known pharmaceutically active compounds particularly used for reducing psychological dependency and during drug abuse.

EFFECT: improved purification of compounds.

21 cl, 8 ex

FIELD: medicine.

SUBSTANCE: lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg of protein and more is used. A preparation for treating mycotic infections contains lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg and more of protein and represents a topical drug.

EFFECT: lower probability of recurrences in treating mycotic infections without normal flora suppression.

10 cl, 4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: for correction of endothelial dysfunction in experiment on rats dysfunction is modelled by preliminary sensitisation of animal with staphylococcus anatoxin in doze 0.1 ml subcutaneously. Then after 24 hours in the same place as anatoxin introduced is suspension of Staphylococcus aureus subcutaneously in dose 60 billions of microbial bodies in 1 ml. After that for following generalisation of infectious agent, daily massage of injection place is carried out. At this background introduced is macrolidal medication azithromycin intragastrically in dose 30 mg/kg/day.

EFFECT: method ensures activation of endothelial dysfunction correction.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: in order to estimate resorbtion function of peritoneum time during which animals achieve stage of surgical sleep in case of intraperitoneal introduction of ethaminal is determined.

EFFECT: method allows to estimate indirectly resoptive function of peritoneum in norm and under impact of aggressive factors.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery. Solution of dye is introduced in proper segmental vessel by direct injection method. Preliminarily, before introduction of dye solution, feeding artery is compressed for 2-3 minutes, dye solution is introduced more distally than compression place and after 1-2 minutes respective vein is compressed. Simultaneously area of supposed staining is influenced by source of constant magnet, placed outside of the organ surface.

EFFECT: method extends arsenal of means for marking intraorgan zones, segments of parenchymatous organs.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to experimental medicine and deals with restoration of reducing with age potential of cell growth of tissues in old laboratory animals. For this purpose medication "Transfer-factor" is introduced to laboratory animals in dose corresponding to 1 capsule a day per 50 kg of weight.

EFFECT: method ensures activation of T-lymphocyte function and restoration of potential of cell growth of salivary gland tissues in said group of animals.

FIELD: medicine.

SUBSTANCE: invention relates to chemical and pharmaceutical industry, namely to creation of medication reducing hematotoxicity of cytostatics. As such medication, polysaccharides from leaves of coltsfoot (Tussilago farfara L.) are used.

EFFECT: medication extends arsenal of preparations increasing efficiency of chemical therapy by reducing henatotoxicity of cytostatics.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to gynecology, and deals with treatment of complicated forms of inflammatory diseases of uterine appendages. For this purpose, when performing abdominal operation from two sides between round ligament of the uterus and isthmic part of fallopian tube medicinal mixtures of the following medications are introduced: at first - lidase 16 U in 1 ml of 0.25% Novocain, after that without removing the needle prednisolone 15 mg, amikacin 0.25 mg in 1 ml of 0.25% Novocain. Drainage of small pelvis with gauze-glove pad on lateral pockets to retrouterine space and bed of remote mass is carried out. In post-operational period antimicrobial drug is introduced intravenously. Limphotropically from two sides from anterior commisure of large pudental lips introduced are medicinal mixtures of medications: first - lidase 16 U in 1 ml of 0.25% Novocain, after that without removing the needle - prednisolone 15 mg, amikacin 0.25 mg in 1 ml of 0.25% Novocain, slowly during 15 minutes. Such introduction is carried out 1 time a day for 7-8 days.

EFFECT: method ensures stimulation of interstitial humoral transport and lymphatic drainage and fast normalisation of clinical and laboratory parametres with reduction of course dose of antimicrobial drugs.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary. The preparation contains the following drugs: L-arginine monohydrochloride in amount 48-72 mg/l, L-lysine monohydrochloride in amount 48-72 mg/l, L-histidine monohydrochloride in amount 13.8-20.8 mg/l, L-isoleucine in amount 13.8-20.8 mg/l, L-leucine in amount 41.6-62.4 mg/l, L-methionine in amount 10.4-15.6 mg/l, L-phenylalanine in amount 17.2-25.8 mg/l, L-threonine in amount 20.8-31.2 mg/l, L-tryptophan in amount 7.9-10.3 mg/l, L-glutamine in amount 68.8-103.2 mg/l, L-valine in amount 17.2-25.8 mg/l, L-tyrosine in amount 27.7-41.5 mg/l, L-cystine monochloride in amount 17.9-26.9 mg/l, L-serine in amount 17.2-25.8 mg/l, glycine in amount 34.4-54.6 mg/l, L-alpha-alanine in amount 17.2-25.8 mg/l, L-proline in amount 25.6-38.4 mg/l, L-aspartic acid in amount 18.0-30.0 mg/l, L-oxyproline in amount 7.9-10.3 mg/l, L-glutamic acid in amount 48-72 mg/l, L-cysteine monohydrochloride in amount 0.12-0.70 mg/l, choline chloride in amount 0.4-3.0 mg/l, folic acid in amount 0.01-0.09 mg/l, calcium pantothenate in amount 0.01-0.09 mg/l, thiamine hydrochloride in amount 0.01-0.09 mg/l, nicotinic acid in amount 0.03-0.22 mg/l, pyridoxal monohydrochloride in amount 0.03-0.22 mg/l, riboflavin in amount 0.012-0.09 mg/l, nicotinamide in amount 0.03-0.22 mg/l, D-biotin in amount 0.01-0.09 mg/l, myoinositol in amount 0.06-0.45 mg/l, pyridoxine hydrochloride in amount 0.03-0.22 mg/l, calciferol in amount 0.01-0.09 mg/l, ascorbic acid in amount 0.06-0.45 mg/l, p-amino-benzoic acid in amount 0.06-0.45 mg/l, glucose in amount 800-1200 mg/l, and the following inorganic salts: sodium chloride in amount 7.2-8.8 g/l, potassium chloride in amount 360-440 mg/l, one-substituted potassium phosphate in amount 54-66 mg/l, two-substituted 12-aqueous sodium phosphate in amount 13.5-16.5 mg/l, 6-aqueous calcium chloride in amount 24.8-30.4 mg/l, 6-aqueous magnesium chloride in amount 9.9-11.6 mg/l, 7-aqueous magnesium sulphate in amount 9.0-11.0 mg/l, 9-aqueous ferrous nitrate in amount 0.65-0.79 mg/l, 3-aqueous sodium acetate in amount 7.1-8.7 mg/l. The method for prevention and correction of diseased conditions in animals consists in the injection introduction in an animal of said preparation in the form of an aqueous solution for prevention 2 times a week for a month in dosage 1.5-2.0 ml per 10 kg of body weight, for therapy in dosage 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, at synthetic and/or food poisoning intoxications - in a tenfold therapeutic dose. And, if a dose of the preparation exceeds 20 ml, it is injected in more points.

EFFECT: invention provides higher therapeutic and preventive effectiveness.

6 cl, 8 tbl

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary. The preparation contains the following drugs: L-arginine monohydrochloride in amount 48-72 mg/l, L-lysine monohydrochloride in amount 48-72 mg/l, L-histidine monohydrochloride in amount 13.8-20.8 mg/l, L-isoleucine in amount 13.8-20.8 mg/l, L-leucine in amount 41.6-62.4 mg/l, L-methionine in amount 10.4-15.6 mg/l, L-phenylalanine in amount 17.2-25.8 mg/l, L-threonine in amount 20.8-31.2 mg/l, L-tryptophan in amount 7.9-10.3 mg/l, L-glutamine in amount 68.8-103.2 mg/l, L-valine in amount 17.2-25.8 mg/l, L-tyrosine in amount 27.7-41.5 mg/l, L-cystine monochloride in amount 17.9-26.9 mg/l, L-serine in amount 17.2-25.8 mg/l, glycine in amount 34.4-54.6 mg/l, L-alpha-alanine in amount 17.2-25.8 mg/l, L-proline in amount 25.6-38.4 mg/l, L-aspartic acid in amount 18.0-30.0 mg/l, L-oxyproline in amount 7.9-10.3 mg/l, L-glutamic acid in amount 48-72 mg/l, L-cysteine monohydrochloride in amount 0.12-0.70 mg/l, choline chloride in amount 0.4-3.0 mg/l, folic acid in amount 0.01-0.09 mg/l, calcium pantothenate in amount 0.01-0.09 mg/l, thiamine hydrochloride in amount 0.01-0.09 mg/l, nicotinic acid in amount 0.03-0.22 mg/l, pyridoxal monohydrochloride in amount 0.03-0.22 mg/l, riboflavin in amount 0.012-0.09 mg/l, nicotinamide in amount 0.03-0.22 mg/l, D-biotin in amount 0.01-0.09 mg/l, myoinositol in amount 0.06-0.45 mg/l, pyridoxine hydrochloride in amount 0.03-0.22 mg/l, calciferol in amount 0.01-0.09 mg/l, ascorbic acid in amount 0.06-0.45 mg/l, p-amino-benzoic acid in amount 0.06-0.45 mg/l, glucose in amount 800-1200 mg/l, and the following inorganic salts: sodium chloride in amount 7.2-8.8 g/l, potassium chloride in amount 360-440 mg/l, one-substituted potassium phosphate in amount 54-66 mg/l, two-substituted 12-aqueous sodium phosphate in amount 13.5-16.5 mg/l, 6-aqueous calcium chloride in amount 24.8-30.4 mg/l, 6-aqueous magnesium chloride in amount 9.9-11.6 mg/l, 7-aqueous magnesium sulphate in amount 9.0-11.0 mg/l, 9-aqueous ferrous nitrate in amount 0.65-0.79 mg/l, 3-aqueous sodium acetate in amount 7.1-8.7 mg/l. The method for prevention and correction of diseased conditions in animals consists in the injection introduction in an animal of said preparation in the form of an aqueous solution for prevention 2 times a week for a month in dosage 1.5-2.0 ml per 10 kg of body weight, for therapy in dosage 3.0-5.0 ml per 10 kg of body weight 2 times a day for 3-5 days, at synthetic and/or food poisoning intoxications - in a tenfold therapeutic dose. And, if a dose of the preparation exceeds 20 ml, it is injected in more points.

EFFECT: invention provides higher therapeutic and preventive effectiveness.

6 cl, 8 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be applied for treatment of T-cell lymphomas and Kaposis's sarcoma. For this purpose 1.5-2 hours before each session of translational immunotherapy photosensitiser is introduced. After that translational immunotherapy is carried out. Translational immunotherapy consists in exfusion of blood, extraction of mononuclear cells with plasma, ultraviolet irradiation, incubation with further reinfusion. Before irradiation moncytes are separated from plasma, monocytes are added in 200-300 ml of physiological solution, irradiation is carried out in flowing mode. Then physiological solution is removed. In obtained material blood plasma is returned and it is incubated at temperature 37°C for 18-24 hours. After it reinfusion is carried out during 30 minutes. Treatment course consists of 4 sessions 2 times per week. Repeated courses are carried out after 4 weeks, 3 months and 6 months.

EFFECT: method allows to reach marked clinical remission in shorter terms, improve patient's life quality, avoid cytotoxic and hormonal medications.

4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to medicine, namely to oncology, and can be used for treatment of metastatic neoplastic disease. Claimed is treatment method which includes introduction of therapeutically efficient quantity of sodium meta-arsenite. Additionally introduction of other chemotherapeutical substance is carried out. Claimed is composition, containing sodium meta-arsenite. Claimed is set for inhibition of abnormal cell growth, which includes therapeutically efficient quantity of pharmaceutical composition, containing sodium meta-arsenite, and other chemotherapeutical substance.

EFFECT: group of inventions ensures possibility of metastatic neoplastic disease treatment with alternative compound with anticancer activity, as well as treatment safety.

2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: synthesis of perineural layer continuity is followed by the injective introduction of a suspension of silicon nanocrystals in the nerve injury area. The injection point is exposed to the thermal and/or electric fields then. The thermal exposure is enabled by a frosted lamp through a red filter. The electric field is generated by alternating voltage electric stimulation -100 mV to +100 mV of frequency 1 to 40 Hz. The thermal and/or electric length exposure is 5 minutes 3 times a day for 7 days.

EFFECT: invention allows reducing time of recovery of nerve fibre conductivity and ensuring faster injured nerve repair.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, gastroenterology. Method includes introduction of glucose, physiological solution, pain-killing medications, vasopressors, antibiotics, Novocain, cytostatics, omeprazole, sandostatin. Novocaine blockades of round ligament of liver, paranephral Novocain blockade by A.A.Vishnevskiy are performed. Large amount of drinking water is introduced. Cooling of abdomen is realised. Additionally, one time for not less than 8 days, electrophoresis with 2% solution of potassium iodide on epigastrium is carried out. After that for not less than an hour cooling of epigastric and umbilical areas of abdomen is performed. During all term of treatment every day patient drinks not less than 500 ml of cooled non-carbonated table soda-alkaline water. Intra-organ galvanic electrophoresis with 2% solution of potassium iodide and 2% solution of Novocain is carried out. Positively charges plate is placed on lumbar region, negatively charged plate is placed on epigastric region. In addition, for not less than 10 days epigastric and lumbar regions one time per day for up to 15 minutes exposed to alternating magnetic field with intensity up to 30 mT.

EFFECT: method improves treatment results, prevents development of destructive forms of disease.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to vascular surgery and can be used in treatment of patients with varicose disease of lower extremities. For this purpose into proximal end of vein introduced is intravascular catheter with its further movement in the same direction as vein trunks to saphenofemoral fistula under constant ultrasonic control of its movement. After that through catheter introduced is phlebosclerosant, as such solution of ozone on the basis of 0.9-2.0% solution of sodium chloride with ozone concentration 10-25 mg per 1 l of sodium chloride solution. Additionally sclerotherapy of varicose tributaries is carried out by puncture introduction of said solution.

EFFECT: method allows to simplify procedure considerably with simultaneous reduction of trauma due to elimination of carrying out crossectomy and eliminate thromboembolic complications due to effect of concentrated ozone solution on blood rheology.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to vascular surgery and can be used in treatment of patients with varicose disease of lower extremities. For this purpose into proximal end of vein introduced is intravascular catheter with its further movement in the same direction as vein trunks to saphenofemoral fistula under constant ultrasonic control of its movement. After that through catheter introduced is phlebosclerosant, as such solution of ozone on the basis of 0.9-2.0% solution of sodium chloride with ozone concentration 10-25 mg per 1 l of sodium chloride solution. Additionally sclerotherapy of varicose tributaries is carried out by puncture introduction of said solution.

EFFECT: method allows to simplify procedure considerably with simultaneous reduction of trauma due to elimination of carrying out crossectomy and eliminate thromboembolic complications due to effect of concentrated ozone solution on blood rheology.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and cattle breeding. Method includes intramuscular or subcutaneous introduction of biogenic stimulator. Stimulator contains (g): 30.0 g of tissue emulsion from bodies of zoophilic fly larvae, 59.8 g of 0.9% solution of table salt in terms of sodium chloride, 10.0 g of natural May bee honey and 0.2 g of formalin. The said medication is introduced to an ill animal in dose 0.02-0.05 ml/kg of weight.

EFFECT: method efficiently activates functioning of protective systems of organism.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and cattle breeding. Method includes intramuscular or subcutaneous introduction of biogenic stimulator. Stimulator contains (g): 30.0 g of tissue emulsion from bodies of zoophilic fly larvae, 59.8 g of 0.9% solution of table salt in terms of sodium chloride, 10.0 g of natural May bee honey and 0.2 g of formalin. The said medication is introduced to an ill animal in dose 0.02-0.05 ml/kg of weight.

EFFECT: method efficiently activates functioning of protective systems of organism.

1 ex

FIELD: medicine.

SUBSTANCE: method involves preparation dental surface, covering it with 30% aqueous solution of silver nitrate and recovery agent for precipitating insoluble silver salts. Silver salts precipitation is carried out by exposing silver nitrate covering tooth surface with halogen radiation of the kind produced by halogen lamp of 12 W or 75 W having spectral bandwidth of 400…500 nm provided with light guide for concentrating luminous flux for 60 s.

EFFECT: enhanced effectiveness of treatment; localized treatment; reduced risk of complications and stress action upon child.

Up!